No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AQST240621P3500
- 0.55
- -0.10-15.38%
15min DelayClose May 31 16:00 ET
0.70High0.55Low
0.70Open0.65Pre Close2 Volume133 Open Interest3.50Strike Price125.00Turnover243.94%IV-14.93%PremiumJun 21, 2024Expiry Date0.62Intrinsic Value100Multiplier19DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.5249Delta0.2466Gamma2.74Leverage Ratio-0.0165Theta-0.0012Rho-1.44Eff Leverage0.0026Vega
Intraday
- 5D
- 1D
News
Express News | Aquestive Therapeutics Announces Two Encore Poster Presentations Highlighting Positive PK And PD Data From Clinical Studies For Anaphylm (Epinephrine) Sublingual Film At The Eastern Allergy Conference From May 30 To June 2
With A 27% Price Drop For Aquestive Therapeutics, Inc. (NASDAQ:AQST) You'll Still Get What You Pay For
Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares have retraced a considerable 27% in the last month, reversing a fair amount of their solid recent performance.
CRSP, NYMT and SBRA Are Among After Hour Movers
Aquestive Therapeutics Initiated at Outperform by Leerink Partners
Aquestive Therapeutics Initiated at Outperform by Leerink Partners
Express News | Leerink Partners Initiates Coverage On Aquestive Therapeutics With Outperform Rating, Announces Price Target of $8
Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target
Aquestive Therapeutics (AQST) has an average rating of buy and price targets ranging from $5.50 to $13, according to analysts polled by Capital IQ.
Comments
$Aquestive Therapeutics(AQST.US$
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
NEWS
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Positive
Successful completion of Phase 3 study for Anaphylm in Q1 2024
Received FDA approval for Libervant for patients ages two to five
Extended cash runway into 2026 through underwritten public offering
Progressed clinical studies for AQST-108 in dermatology conditions
Increase in total revenues from $11.1 million in Q1 2023 to $12.1 million in Q1 2024
Negati...
2
3
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
7
2
$Aquestive Therapeutics(AQST.US$ they trying to beat down price prior to earning reporting. then will shoot up. NFA
1
Read more
JESSE JAMES8832 : let it get beat down so i can buy it up
Jaguar8OP JESSE JAMES8832: Your wish will be granted
JESSE JAMES8832 Jaguar8OP: at least i get my way somehow llol